|Therapeutic Class:||Hepatic viral infections (Hepatitis B)|
|Manufacturer:||Sun Pharmaceutical (Bangladesh) Limited|
|Last Updated:||2020-11-20 18:15:00|
Adfovir Tablet contains Adefovir Dipivoxil. Adfovir uses:
Adefovir Dipivoxil is indicated for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
Adfovir Tablet contains Adefovir Dipivoxil 10 mg. Adfovir doses:
The recommended dose of Adefovir for the treatment of chronic hepatitis B in adolescent & adults (age ≥ 12 year) with adequate renal function is 10 mg, once daily, taken orally, without regard to food
Dose Adjustment in Renal Impairment: Significantly increased drug exposures are seen when Adefovir Dipivoxil is administered to patients with renal impairment. Therefore, the dosing interval of Adefovir Dipivoxil should be adjusted in patients with baseline creatinine clearance < 50 mL/min using the following suggested guidelines-
Dosing interval adjustment of Adefovir in patients with renal impairment
20 to 49
10 to 19
< 10 Hemodialysis or CAPD
Recommended dose and dosing interval
10 mg every 24 hours
10 mg every 48 hours
10 mg every 72 hours
10 mg every 7 days
Treatment-related clinical adverse events that occurred in 3% or greater of Adefovir Dipivoxil-treated patients compared with placebo are asthenia, headache, abdominal pain, nausea, flatulence, diarrhea, dyspepsia.
Adefovir is an acyclic nucleotide analogue of adenosine monophosphate. Adefovir is phosphorylated to the active metabolite, Adefovir diphosphate, by cellular kinases. Adefovir diphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate deoxyadenosine triphosphate and by causing DNA chain termination after its incorporation into viral DNA.
Severe acute exacerbation of hepatitis has been reported in patients who have discontinued anti-hepatitis B therapy, including therapy with Adefovir Dipivoxil. Patients who discontinue Adefovir Dipivoxil should be monitored at repeated intervals over a period of time for hepatic function. If appropriate, resumption of anti-hepatitis B therapy may be warranted.
Chronic administration of Adefovir Dipivoxil (10 mg once daily) may result in nephrotoxicity. The overall risk of nephrotoxicity in patients with adequate renal function is low.
However, this is of special importance in patients at risk of or having underlying renal dysfunction and patients taking concomitant nephrotoxic agents such as cyclosporine, tacrolimus, aminoglycosides, vancomycin and non-steroidal anti-inflammatory drugs.
The pharmacokinetics of adefovir was unchanged when adefovir dipivoxil was coadministered with lamivudine, trimethoprim/ sulfamethoxazole and acetaminophen. When adefovir dipivoxil was co-administered with ibuprofen (800 mg three times daily), increases in adefovir Cmax (33%), AUC (23%) and urinary recovery were observed due to higher oral bioavailability of adefovir.
Pregnancy: There are no adequate and well-controlled studies in pregnant women. Therfore, Adefovir Dipivoxil should be used during pregnancy only if clearly needed and after careful consideration of the risks and benefits.
Lactation: It is not known whether Adefovir is excreted in human milk. Mothers should be instructed not to breast-feed if they are taking Adefovir Dipivoxil.
Safety and effectiveness in pediatric patients have not been established.
In general, caution should be exercised when prescribing to elderly patients since they have greater frequency of decreased renal or cardiac function due to concomitant disease or other drug therapy.
Adefovir dipivoxil is contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the product.
Pediatric use: Safety and effectiveness in pediatric patients have not been established.
Geriatric use: In general, caution should be exercised when prescribing to elderly patients since they have greater frequency of decreased renal or cardiac function due to concomitant disease or other drug therapy.
Dose Adjustment in Renal Impairment: the dosing interval of Adefovir should be adjusted in patients with baseline creatinine clearance <50 ml/min using the following suggested guidelines:
If overdose occurs the patient must be monitored for evidence of toxicity, and standard supportive treatment applied as necessary.
Store at cool and dry place. Protect from light and moisture. Keep all the medicines out of the reach of children.
Adfovir Tablet price in Bangladesh 35.14